Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
Journal of Liver Cancer
;
: 57-62, 2016.
Artículo
en Coreano
| WPRIM
| ID: wpr-194395
ABSTRACT
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fosfotransferasas
/
Proteínas Tirosina Quinasas
/
Resultado del Tratamiento
/
Carcinoma Hepatocelular
/
Trombosis de la Vena
/
Receptores de Factores de Crecimiento Endotelial Vascular
/
Quimioterapia
/
Pulmón
/
Metástasis de la Neoplasia
Límite:
Humanos
Idioma:
Coreano
Revista:
Journal of Liver Cancer
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS